Pimavanserin tartrate

Pimavanserin tartrate

• Patent application: innovative purification method
• Patent application: key intermediate crystallization
• Product purity ~100%
• Free from nitrosamine risk
• Tailor-made PSD
• Time-efficient process
• Phosgene excluded from the process
• Regeneration of solvents

Status	Pipeline
Therapeutic cat.	Neurology
Polymorphic form	Crystalline anhydrous form C
CAS No.	706782-28-7
EU DMF readiness
US DMF readiness

Drug description

Pimavanserin is an antipsychotic medicine that works by changing the actions of chemicals in the brain. Pimavanserin is used to treat hallucinations and delusions caused by psychosis that is related to Parkinson's disease. Pimavanserin may also be used for purposes not listed in this medication guide.

Disclaimer: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Dapagliflozin (amorphous), Linagliptin, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulationare met.